Loading...

We've got a brand new version of Simply Wall St! Try it out

NeoGenomics

Nasdaq:NEO
Snowflake Description

Excellent balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NEO
Nasdaq
$3B
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

NeoGenomics, Inc., together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. The last earnings update was 10 days ago. More info.


Add to Portfolio Compare Print
NEO Share Price and Events
7 Day Returns
-2.1%
NasdaqCM:NEO
-0.5%
US Life Sciences
-1%
US Market
1 Year Returns
99.2%
NasdaqCM:NEO
10.4%
US Life Sciences
-0.4%
US Market
NEO Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
NeoGenomics (NEO) -2.1% 7.3% 9.8% 99.2% 204.5% 376.2%
US Life Sciences -0.5% -4% 3.3% 10.4% 68.7% 100.3%
US Market -1% -3.3% 0.4% -0.4% 30.4% 37.1%
1 Year Return vs Industry and Market
  • NEO outperformed the Life Sciences industry which returned 10.4% over the past year.
  • NEO outperformed the Market in United States of America which returned -0.4% over the past year.
Price Volatility
NEO
Industry
5yr Volatility vs Market

Value

 Is NeoGenomics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of NeoGenomics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for NeoGenomics.

NasdaqCM:NEO Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 8 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.9%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqCM:NEO
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Life Sciences Unlevered Beta Simply Wall St/ S&P Global 1.01
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.01 (1 + (1- 21%) (5.32%))
1.035
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.04
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.035 * 5.96%)
8.9%

Discounted Cash Flow Calculation for NasdaqCM:NEO using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for NeoGenomics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

NasdaqCM:NEO DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.9%)
2020 26.60 Analyst x1 24.43
2021 45.10 Analyst x1 38.03
2022 61.77 Est @ 36.97% 47.83
2023 78.26 Est @ 26.69% 55.65
2024 93.53 Est @ 19.51% 61.07
2025 107.06 Est @ 14.47% 64.19
2026 118.79 Est @ 10.95% 65.40
2027 128.86 Est @ 8.48% 65.15
2028 137.57 Est @ 6.76% 63.87
2029 145.21 Est @ 5.55% 61.91
Present value of next 10 years cash flows $547.53
NasdaqCM:NEO DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $145.21 × (1 + 2.73%) ÷ (8.9% – 2.73%)
$2,418.04
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $2,418.04 ÷ (1 + 8.9%)10
$1,030.91
NasdaqCM:NEO Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $547.53 + $1,030.91
$1,578.44
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $1,578.44 / 103.86
$15.2
NasdaqCM:NEO Discount to Share Price
Calculation Result
Value per share (USD) From above. $15.20
Current discount Discount to share price of $25.24
= -1 x ($25.24 - $15.20) / $15.20
-66.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of NeoGenomics is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for NeoGenomics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are NeoGenomics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:NEO PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in USD $0.02
NasdaqCM:NEO Share Price ** NasdaqCM (2019-08-16) in USD $25.24
United States of America Life Sciences Industry PE Ratio Median Figure of 21 Publicly-Listed Life Sciences Companies 34.35x
United States of America Market PE Ratio Median Figure of 3,095 Publicly-Listed Companies 17.23x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of NeoGenomics.

NasdaqCM:NEO PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:NEO Share Price ÷ EPS (both in USD)

= 25.24 ÷ 0.02

1215.8x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • NeoGenomics is overvalued based on earnings compared to the US Life Sciences industry average.
  • NeoGenomics is overvalued based on earnings compared to the United States of America market.
Price based on expected Growth
Does NeoGenomics's expected growth come at a high price?
Raw Data
NasdaqCM:NEO PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 1215.8x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts
103.6%per year
United States of America Life Sciences Industry PEG Ratio Median Figure of 19 Publicly-Listed Life Sciences Companies 2.74x
United States of America Market PEG Ratio Median Figure of 2,124 Publicly-Listed Companies 1.4x

*Line of best fit is calculated by linear regression .

NasdaqCM:NEO PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 1215.8x ÷ 103.6%

11.73x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • NeoGenomics is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on NeoGenomics's assets?
Raw Data
NasdaqCM:NEO PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in USD $4.72
NasdaqCM:NEO Share Price * NasdaqCM (2019-08-16) in USD $25.24
United States of America Life Sciences Industry PB Ratio Median Figure of 37 Publicly-Listed Life Sciences Companies 4.67x
United States of America Market PB Ratio Median Figure of 5,265 Publicly-Listed Companies 1.7x
NasdaqCM:NEO PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:NEO Share Price ÷ Book Value per Share (both in USD)

= 25.24 ÷ 4.72

5.35x

* Primary Listing of NeoGenomics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • NeoGenomics is overvalued based on assets compared to the US Life Sciences industry average.
X
Value checks
We assess NeoGenomics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check)
  5. NeoGenomics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is NeoGenomics expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
103.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is NeoGenomics expected to grow at an attractive rate?
  • NeoGenomics's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • NeoGenomics's earnings growth is expected to exceed the United States of America market average.
  • NeoGenomics's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:NEO Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqCM:NEO Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts 103.6%
NasdaqCM:NEO Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 8 Analysts 12.7%
United States of America Life Sciences Industry Earnings Growth Rate Market Cap Weighted Average 14.3%
United States of America Life Sciences Industry Revenue Growth Rate Market Cap Weighted Average 7.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:NEO Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:NEO Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 502 65 37 3
2020-12-31 447 45 17 8
2019-12-31 400 18 3 8
NasdaqCM:NEO Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-06-30 343 25 2
2019-03-31 309 37 6
2018-12-31 277 45 6
2018-09-30 262 35 8
2018-06-30 252 34 -1
2018-03-31 246 34 -9
2017-12-31 240 18 -11
2017-09-30 239 12 -27
2017-06-30 241 14 -26
2017-03-31 242 13 -29
2016-12-31 232 21 -31
2016-09-30 211 24 -18

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • NeoGenomics's earnings are expected to grow significantly at over 20% yearly.
  • NeoGenomics's revenue is expected to grow by 12.7% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:NEO Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below

All data from NeoGenomics Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:NEO Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 0.34 0.34 0.34 2.00
2020-12-31 0.16 0.21 0.10 6.00
2019-12-31 0.03 0.06 0.00 6.00
NasdaqCM:NEO Past Financials Data
Date (Data in USD Millions) EPS *
2019-06-30 0.02
2019-03-31 0.07
2018-12-31 0.07
2018-09-30 0.09
2018-06-30 -0.02
2018-03-31 -0.12
2017-12-31 -0.14
2017-09-30 -0.34
2017-06-30 -0.33
2017-03-31 -0.37
2016-12-31 -0.40
2016-09-30 -0.24

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • NeoGenomics is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess NeoGenomics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
NeoGenomics has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has NeoGenomics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare NeoGenomics's growth in the last year to its industry (Life Sciences).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • NeoGenomics's year on year earnings growth rate was negative over the past 5 years, however the most recent earnings are above average.
  • NeoGenomics has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • NeoGenomics has become profitable in the last year making it difficult to compare the US Life Sciences industry average.
Earnings and Revenue History
NeoGenomics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from NeoGenomics Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:NEO Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 342.86 1.94 140.39 4.77
2019-03-31 308.90 5.88 127.66 3.25
2018-12-31 276.74 6.09 109.41 3.00
2018-09-30 261.69 7.59 102.29 3.03
2018-06-30 251.73 -1.35 99.64 3.86
2018-03-31 246.25 -9.42 95.54 3.73
2017-12-31 240.25 -10.94 94.36 3.64
2017-09-30 239.32 -27.00 97.66 4.01
2017-06-30 240.94 -25.72 98.01 3.71
2017-03-31 241.81 -28.72 98.55 4.07
2016-12-31 231.81 -30.82 87.84 4.65
2016-09-30 210.87 -17.80 84.80 5.58
2016-06-30 175.24 -12.29 70.00 5.48
2016-03-31 136.48 -7.31 54.88 4.98
2015-12-31 99.80 -2.66 40.51 4.20
2015-09-30 97.52 -0.02 39.34 2.76
2015-06-30 95.61 -0.18 38.51 2.90
2015-03-31 91.91 0.27 37.56 2.73
2014-12-31 87.07 1.13 35.81 2.69
2014-09-30 80.39 0.94 33.38 2.92
2014-06-30 74.06 2.13 30.70 2.25
2014-03-31 68.99 2.13 27.70 2.23
2013-12-31 66.47 2.03 26.12 2.44
2013-09-30 63.04 1.06 24.60 2.24
2013-06-30 60.36 -0.81 23.70 2.71
2013-03-31 60.36 -0.54 23.66 2.62
2012-12-31 59.87 0.07 23.34 2.28
2012-09-30 57.87 0.33 22.89 1.96

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • NeoGenomics has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • NeoGenomics used its assets less efficiently than the US Life Sciences industry average last year based on Return on Assets.
  • NeoGenomics has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess NeoGenomics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
NeoGenomics has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is NeoGenomics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up NeoGenomics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • NeoGenomics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • NeoGenomics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of NeoGenomics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from NeoGenomics Company Filings, last reported 1 month ago.

NasdaqCM:NEO Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 489.73 101.35 167.44
2019-03-31 323.85 100.17 13.20
2018-12-31 320.44 100.75 9.81
2018-09-30 303.56 96.98 118.44
2018-06-30 164.21 127.27 9.44
2018-03-31 208.02 88.54 15.17
2017-12-31 204.58 94.95 12.82
2017-09-30 199.66 95.79 12.21
2017-06-30 196.57 99.19 10.93
2017-03-31 194.02 100.06 11.04
2016-12-31 186.60 95.90 12.53
2016-09-30 246.09 52.84 28.94
2016-06-30 243.37 52.88 21.79
2016-03-31 240.17 52.91 19.26
2015-12-31 238.11 61.81 23.42
2015-09-30 61.85 0.00 33.97
2015-06-30 60.87 0.00 32.95
2015-03-31 60.16 0.00 31.25
2014-12-31 60.41 0.13 33.69
2014-09-30 59.07 0.00 34.37
2014-06-30 23.13 1.99 5.02
2014-03-31 22.50 4.86 5.39
2013-12-31 21.71 4.28 4.83
2013-09-30 20.33 2.74 4.93
2013-06-30 19.44 3.19 4.64
2013-03-31 18.83 4.19 4.63
2012-12-31 9.22 8.46 1.87
2012-09-30 9.22 8.04 2.04
  • NeoGenomics's level of debt (20.7%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (8.4% vs 20.7% today).
  • Debt is well covered by operating cash flow (24.9%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 3.1x coverage).
X
Financial health checks
We assess NeoGenomics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. NeoGenomics has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is NeoGenomics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from NeoGenomics dividends.
If you bought $2,000 of NeoGenomics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate NeoGenomics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate NeoGenomics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:NEO Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
United States of America Life Sciences Industry Average Dividend Yield Market Cap Weighted Average of 7 Stocks 0.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2009 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqCM:NEO Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as NeoGenomics has not reported any payouts.
  • Unable to verify if NeoGenomics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of NeoGenomics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as NeoGenomics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess NeoGenomics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can NeoGenomics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. NeoGenomics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of NeoGenomics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Doug VanOort
COMPENSATION $3,347,219
AGE 64
TENURE AS CEO 9.8 years
CEO Bio

Mr. Douglas M. VanOort, also known as Doug, has been the Chairman and Chief Executive Officer of NeoGenomics Inc. since October 28, 2009. Mr. VanOort has been the Executive Chairman and Chief Executive Officer at NeoGenomics Laboratories, Inc. since March 2009. He joined Neogenomics on November 1, 2004.. Prior to joining NeoGenomics, Mr. VanOort was a General Partner with a private equity firm and a Founding Managing Partner of a venture capital firm. He has been a Co-Owner of Vision Ace Hardware, LLC since 2000. He serves as Managing Director of Conundrum Capital Partners, LLC and has been its Founding Partner since 2000. He gained his business strategy, operations, finance and organizational development expertise in leadership positions from 20 years of experience with both Fortune 500 firms and entrepreneurial ventures. Previously, he served as the Chairman of the Board, Executive Chairman and Interim Chief Executive Officer of Neogenomics Inc. from March 2009 to October 2009. From 1982 through 1999, Mr. VanOort served in various positions at Corning Incorporated and at its spin-off company, Quest Diagnostics, Inc. Mr. VanOort was an Operating Partner at Summer Street Capital Partners, L.L.C. From 2000 to 2001, he served as the President and Chief Executive Officer of USA Datanet, Inc. From 1996 to 1999, he served as the Chief Operating Officer at Quest Diagnostics Inc. and also served as its Senior Vice President of Operations from 1995 to 1999. From 1982 to 1995, he served in various executive capacities at Corning Incorporated, including Executive Vice President and Chief Financial Officer of Corning Life Sciences B.V., Director of Mergers and Acquisitions and in a variety of divisional and corporate level financial positions. Mr. VanOort served as Chairman of the Board at USA Datanet, Inc. until April 2005. He has been an Independent Director at BioHiTech Global, Inc. since August 2015. He serves as a Director Swift Start Corp. He serves as a Director of Reichert Inc., ICE, UStec, Prism Health Networks and several other privately held firms, publicly traded firms and charitable organizations. He served as a Director at USA Datanet from 2000 to 2001. He served as a Director of Palladian Health, LLC. Mr. VanOort is a graduate of Bentley University.

CEO Compensation
  • Doug's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Doug's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the NeoGenomics management team in years:

1.7
Average Tenure
53
Average Age
  • The average tenure for the NeoGenomics management team is less than 2 years, this suggests a new team.
Management Team

Doug VanOort

TITLE
Chairman & CEO
COMPENSATION
$3M
AGE
64
TENURE
9.8 yrs

Larry Weiss

TITLE
Chief Scientific Officer
COMPENSATION
$856K
AGE
62
TENURE
0.7 yrs

Bill Bonello

TITLE
Chief Strategy & Corporate Development Officer and Director of Investor Relations
COMPENSATION
$820K
AGE
54
TENURE
1.3 yrs

George Cardoza

TITLE
President of Pharma Services Division
COMPENSATION
$1M
AGE
57

Rob Shovlin

TITLE
President of Clinical Services Division
COMPENSATION
$1M
AGE
48
TENURE
3.4 yrs

Sharon Virag

TITLE
Strategic Advisor
COMPENSATION
$1M
AGE
52

Kathryn McKenzie

TITLE
Chief Accounting Officer
AGE
35
TENURE
1.8 yrs

Steve Ross

TITLE
VP & Chief Information Officer
COMPENSATION
$508K
AGE
55
TENURE
6.3 yrs

Stephanie Bywater

TITLE
Chief Compliance Officer
AGE
48
TENURE
1.3 yrs

John Park

TITLE
Chief Marketing Officer
AGE
50
TENURE
1.6 yrs
Board of Directors Tenure

Average tenure and age of the NeoGenomics board of directors in years:

4.5
Average Tenure
61
Average Age
  • The tenure for the NeoGenomics board of directors is about average.
Board of Directors

Doug VanOort

TITLE
Chairman & CEO
COMPENSATION
$3M
AGE
64
TENURE
9.8 yrs

Raymond Hipp

TITLE
Independent Director
COMPENSATION
$161K
AGE
76
TENURE
8.5 yrs

Bruce Crowther

TITLE
Director
COMPENSATION
$161K
AGE
67
TENURE
4.8 yrs

Lynn Tetrault

TITLE
Director
COMPENSATION
$161K
AGE
56
TENURE
4.2 yrs

Steve Kanovsky

TITLE
Director
AGE
56
TENURE
2.1 yrs

Steve Jones

TITLE
Director
COMPENSATION
$365K
AGE
56
TENURE
1.6 yrs

Kevin Johnson

TITLE
Independent Director
COMPENSATION
$146K
AGE
64
TENURE
8.8 yrs

Alison Hannah

TITLE
Director
COMPENSATION
$176K
AGE
58
TENURE
4.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
15. Nov 18 Sell Aspen Capital Group Company 12. Nov 18 14. Nov 18 -135,398 $16.69 $-2,256,066
01. Mar 19 Sell Aspen Capital Group Company 26. Feb 19 27. Feb 19 -264,602 $19.24 $-5,004,963
10. May 19 Sell Raymond Hipp Individual 07. May 19 08. May 19 -150,000 $22.61 $-3,361,880
01. Mar 19 Sell Steven Jones Individual 26. Feb 19 27. Feb 19 -35,271 $19.27 $-663,780
14. Dec 18 Sell General Electric Company Company 14. Dec 18 14. Dec 18 -10,835,145 $12.00 $-130,021,740
21. Nov 18 Sell Lynn Tetrault Individual 19. Nov 18 19. Nov 18 -13,000 $16.00 $-207,940
15. Nov 18 Sell Steven Jones Individual 13. Nov 18 14. Nov 18 -5,729 $16.66 $-95,169
13. Nov 18 Sell General Electric Company Company 09. Nov 18 09. Nov 18 -4,164,855 $16.75 $-69,761,321
13. Nov 18 Sell Kevin Johnson Individual 09. Nov 18 09. Nov 18 -66,007 $17.08 $-1,124,180
X
Management checks
We assess NeoGenomics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. NeoGenomics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Investors Who Bought NeoGenomics (NASDAQ:NEO) Shares Five Years Ago Are Now Up 401%

Fortunately, the market has not missed this, and has pushed the share price up by 38% per year in that time. … Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. … If you would like to research NeoGenomics in more detail then you might want to take a look at whether insiders have been buying or selling shares in the company.

Simply Wall St -

One Thing To Remember About The NeoGenomics, Inc. (NASDAQ:NEO) Share Price

Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market. … Check out our latest analysis for NeoGenomics What we can learn from NEO's beta value Given that it has a beta of 0.86, we can surmise that the NeoGenomics share price has not been strongly impacted by broader market volatility (over the last 5 years).

Simply Wall St -

Is NeoGenomics, Inc.'s (NASDAQ:NEO) CEO Pay Fair?

First, this article will compare CEO compensation with compensation at similar sized companies. … Check out our latest analysis for NeoGenomics How Does Doug VanOort's Compensation Compare With Similar Sized Companies? … is worth US$2.2b, and total annual CEO compensation is US$3.3m.

Simply Wall St -

How Financially Strong Is NeoGenomics, Inc. (NASDAQ:NEO)?

On top of this, NEO has produced US$37m in operating cash flow in the last twelve months, leading to an operating cash to total debt ratio of 28%, meaning that NEO’s operating cash is sufficient to cover its debt. … At the current liabilities level of US$73m, it appears that the company has been able to meet these obligations given the level of current assets of US$116m, with a current ratio of 1.59x. … Next Steps: Although NEO’s debt level is towards the higher end of the spectrum, its cash flow coverage seems adequate to meet obligations which means its debt is being efficiently utilised.

Simply Wall St -

NeoGenomics (NASDAQ:NEO) Shareholders Have Enjoyed A Whopping 551% Share Price Gain

(NASDAQ:NEO) share price has soared 551% over five years. … It's also good to see the share price up 25% over the last quarter. … We think revenue is probably a better guide.

Simply Wall St -

Is NeoGenomics, Inc. (NASDAQ:NEO) A Financially Sound Company?

(NASDAQ:NEO) with its market cap of US$2.0b, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn. … Understanding the company's financial health becomes. … The following basic checks can help you get a picture of the company's balance sheet strength.

Simply Wall St -

Based On Its ROE, Is NeoGenomics, Inc. (NASDAQ:NEO) A High Quality Stock?

With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business. … Another way to think of that is that for every $1 worth of equity in the company, it was able to earn $0.0082. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Is NeoGenomics, Inc.'s (NASDAQ:NEO) CEO Overpaid Relative To Its Peers?

This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … And finally - as a second measure of performance - we will look at the returns shareholders have received over the last few years. … How Does Doug VanOort's Compensation Compare With Similar Sized Companies?

Simply Wall St -

Do Institutions Own NeoGenomics, Inc. (NASDAQ:NEO) Shares?

Generally speaking, as a company grows, institutions will increase their ownership. … Conversely, insiders often decrease their ownership over time. … We can zoom in on the different ownership groups, to learn more about NEO

Simply Wall St -

What Investors Should Know About NeoGenomics, Inc.'s (NASDAQ:NEO) Financial Strength

(NASDAQ:NEO) is a small-cap stock with a market capitalization of US$1.1b. … While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end up ignoring a key aspect, which could be the biggest threat to its existence: its financial health. … Evaluating financial health as part of your investment thesis is

Simply Wall St -

Company Info

Description

NeoGenomics, Inc., together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company’s laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services, which focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. The company also provides pathology consultation services for clients in which its pathologists review surgical samples on a consultative basis; and testing services in support of its pharmaceutical clients’ oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

Details
Name: NeoGenomics, Inc.
NEO
Exchange: NasdaqCM
Founded: 2001
$2,621,399,014
103,858,915
Website: http://www.neogenomics.com
Address: NeoGenomics, Inc.
12701 Commonwealth Drive,
Suite 9,
Fort Myers,
Florida, 33913,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM NEO Common Stock Nasdaq Capital Market US USD 23. Nov 2001
DB NG9 Common Stock Deutsche Boerse AG DE EUR 23. Nov 2001
BMV NEO * Common Stock Bolsa Mexicana de Valores MX MXN 23. Nov 2001
Number of employees
Current staff
Staff numbers
1,500
NeoGenomics employees.
Industry
Life Sciences Tools and Services
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/08/17 23:44
End of day share price update: 2019/08/16 00:00
Last estimates confirmation: 2019/08/08
Last earnings filing: 2019/08/07
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.